Do you want to read an article? Please log in or register.
Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study
Myocardial Infarction
Related content
COMMENTED
Cardiovascular Risk and Diseases
Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW
doi: 10.1016/S2213-8587(25)00165-2
Cardiovascular Risk and Diseases
Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study
Diabetes Obes Metab
Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J
doi: 10.1111/dom.70214
Myocardial Infarction
Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare Beneficiaries
Circ Cardiovasc Qual Outcomes
Mentias A, Keshvani N, Desai MY, Kapadia S, Ziada KM, McCarthy CP, Hall HM, Park K, Kumbhani DJ, Lincoff AM, Januzzi JL Jr, Pandey A
doi: 10.1161/CIRCOUTCOMES.125.012136
Myocardial Infarction
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study
Lancet Diabetes Endocrinol
Smidtslund P, Harjutsalo V, Thorn V, Jansson Sigfrids F, Groop PH, Thorn LM, FinnDiane Study Group
doi: 10.1016/S2213-8587(25)00368-7
Cardiovascular Risk and Diseases
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies
Ann Intern Med
Saeed A, Mulukutla SR, Thoma F, Lemon L, Koczo A, Reis S, Marroquin O, Kip K
doi: 10.7326/ANNALS-24-00775
Cardiovascular Risk and Diseases
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Diabetes Obes Metab
Nanna MG, Doan QV, Fabricatore A, Faurby M, Henry AD, Houshmand-Oeregaard AS, Levine A, Navar AM, Scassellati Sforzolini T, Toliver JC
doi: 10.1111/dom.16370
Heart Failure
Prognostic Impact of Cardiovascular-Kidney-Metabolic Overlap Among Patients With Acute Heart Failure: Insights From a Real-World Multinational Cohort
J Am Heart Assoc
Marchetti M, Antiochos P, Pitta-Gros B, Abdurashidova T, Soborun N, Monney P, Yerly P, Tzimas G, Skalidis I, Vollenweider P, Gencer B, Fakhouri F, Vaduganathan M, Hullin R, Lu H
doi: 10.1161/JAHA.125.045294
Heart, Artery and Coronary Diseases
Association between SSRI use and cardiovascular outcomes in patients with coronary artery disease and generalized anxiety disorder: A real-world cohort study
Atherosclerosis
Wu JY, Chang HY, Kao CL, Hung KC, Yu T, Lin YM
doi: 10.1016/j.atherosclerosis.2025.120390
Atrial Fibrillation
Inverse association between remnant cholesterol and risks of atrial fibrillation among patients with type 2 diabetes
Front Endocrinol (Lausanne)
Jiang Z, Zhao K, Sun M, Sun J, Pan S
doi: 10.3389/fendo.2025.1461613